Induction of Sustained Clinical Remission in Early Axial Spondyloarthritis Following Certolizumab Pegol Treatment: 48-Week Outcomes from C-OPTIMISE

Rheumatology and Therapy
R LandewéLianne Gensler

Abstract

Achievement of remission is a key treatment goal for patients with axial spondyloarthritis (axSpA). C-OPTIMISE assessed achievement of sustained clinical remission in patients with axSpA, including radiographic (r) and non-radiographic (nr) axSpA, during certolizumab pegol (CZP) treatment, and subsequent maintenance of remission following CZP dose continuation, dose reduction or withdrawal. Here, we report outcomes from the first 48 weeks (induction period) of C-OPTIMISE, during which patients received open-label CZP. C-OPTIMISE (NCT02505542) was a two-part, multicenter, phase 3b study in adult patients with early axSpA (r-/nr-axSpA), including a 48-week open-label induction period followed by a 48-week maintenance period. Patients with active adult-onset axSpA, < 5 years' symptom duration, and fulfilling Assessment of SpondyloArthritis international Society classification criteria, were included. During the induction period, patients received a loading dose of CZP 400 mg at weeks 0, 2, and 4, followed by CZP 200 mg every 2 weeks (Q2W) up to week 48. The main outcome of the 48-week induction period was the achievement of sustained clinical remission (defined as an Ankylosing Spondylitis Disease Activity Score [ASDAS] < 1.3 at w...Continue Reading

References

Dec 14, 2002·Annals of the Rheumatic Diseases·L C DowardM A Chamberlain
Nov 12, 2010·Annals of the Rheumatic Diseases·Pedro MachadoUNKNOWN Assessment of SpondyloArthritis international Society
Mar 22, 2013·Therapeutic Advances in Musculoskeletal Disease·Denis Poddubnyy
Aug 29, 2013·Arthritis and Rheumatism·Adrian CiureaUNKNOWN Rheumatologists of the Swiss Clinical Quality Management Program for Axial Spondyloarthritis
Feb 19, 2014·Annals of the Rheumatic Diseases·Jan SørensenUNKNOWN all departments of rheumatology in Denmark
Nov 6, 2014·The New England Journal of Medicine·Paul EmeryBonnie Vlahos
Jul 28, 2016·Joint, Bone, Spine : Revue Du Rhumatisme·Vanina Masson BeharLaure Gossec
Jan 15, 2017·Annals of the Rheumatic Diseases·Désirée van der HeijdeJürgen Braun
Mar 25, 2017·Rheumatology·Christopher J EdwardsKlaus Kruger
Sep 25, 2017·Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases·Vibeke Strand, Jasvinder A Singh
Dec 24, 2017·Arthritis Research & Therapy·Nilasha Ghosh, Eric M Ruderman
Feb 18, 2018·Annals of the Rheumatic Diseases·Pedro M MachadoUNKNOWN Assessment of SpondyloArthritis international Society (ASAS)
May 17, 2018·Open Access Rheumatology : Research and Reviews·Josefina MarinEnrique R Soriano
Oct 26, 2018·Arthritis Care & Research·Sofia RamiroPascal Claudepierre
Nov 18, 2018·Rheumatology·Helena Marzo-OrtegaKarl Gaffney
Dec 28, 2018·Clinical Rheumatology·Abhijeet Danve, Atul Deodhar
May 9, 2019·Joint, Bone, Spine : Revue Du Rhumatisme·Krystel AouadXenofon Baraliakos
Nov 30, 2019·ACR Open Rheumatology·Muhammad A Khan, Sjef van der Linden
May 10, 2020·Annals of the Rheumatic Diseases·Robert Bm LandewéLianne Gensler

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT02505542
NCT01087762
NCT02552212

Software Mentioned

Geog
OPTIMISE
axSpAnd

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.